Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986. Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse. In this retrospective study, the results of autologous and allogeneic SCT in these populations were evaluated. In total, 187 patients with a median age of 34 years (17-66 years) underwent SCT. The 5-year diseasefree survival (DFS), for all patients, was 26% (Confidence intervals (CI) 20-32%). The 5-year DFS was higher for patients transplanted in first remission 32% (CI 24-40%) compared to 14% (CI 5-23%; Po0.0001) in patients transplanted beyond first remission. No significant differences in DFS (P ¼ 0.06) were determined between autologous, related donor and unrelated donor SCT in the whole cohort. A lower relapse rate was counterbalanced by higher treatment-related mortality in patients undergoing allogeneic SCT. In Philadelphia-positive ALL, allogeneic SCT was superior to autologous SCT, with a 5-year DFS of 30% (CI 12-47%) vs 0% (P ¼ 0.04). Limited chronic graft-versus-host-disease (GVHD) was associated with an improved DFS of 53% (CI 38-69%) compared to no chronic GVHD of 22% (CI 10-36%; P ¼ 0.0008), indicating a clinically important graft-versus-leukaemia effect.
cell transplantation; graft versus host disease Although modern chemotherapy treatment for adults with acute lymphoblastic leukaemia (ALL) has resulted in high remission rates, long-term survival has only moderately improved during the last years with disease-free survivals (DFS) of 30-40%, 1 relapse remaining the main cause of death. Stem cell transplantation (SCT) was introduced as an alternative post-remission therapy, mainly for patients with ALL considered as having a high risk of relapse. Allogeneic SCT transplantation is superior to maintenance chemotherapy or autologous SCT in Philadelphia chromosome (Ph)-positive ALL [2] [3] [4] and is usually recommended in first remission for these patients. There are limited and conflicting data, based on ALL subtype, age and risk factors, concerning when to recommend chemotherapy maintenance, autologous or allogeneic SCT in Phnegative patients. The existence of a graft-versus-leukaemia-effect (GVL) has been questioned for ALL, but in recent studies lower relapse rates for patients with graftversus-host-disease (GVHD) [5] [6] [7] have been reported, indicating that GVL is effective in ALL treatment.
In Sweden, adult patients (416 years) with ALL have been treated according to national protocols since 1986. In this retrospective study, the outcome of consecutive ALL patients, diagnosed between 1986 and 2000, undergoing SCT at any of the eight transplantation centres in Sweden, was analysed. Objectives were to evaluate the results for autologous, related donor (RD) and unrelated donor (URD) SCT and to identify subgroups of patients who may benefit from either type of transplant.
Patients and methods

Patients
The majority of adult patients diagnosed with ALL in Sweden during 1986-2000 were treated uniformly according to national protocols. Between 1986 and 1993, the national treatment protocol consisted of a traditional ALL treatment adopted from the L-10 protocol 8 (Table 1a) . From 1994, the national treatment protocol concerning pre-B and T-ALL and acute undifferentiated leukaemia (AUL) consisted of an intensive chemotherapy regimen with high-dose cytarabine up-front 9 (Table 1b) . During both periods, central nervous system prophylaxis consisted of intrathecal (i.t.) methotrexate, in the first period combined with CNS irradiation. After 1994, patients with mature B-ALL were treated according to the 'NHL-BFM 90 protocol'. 10, 11 In both periods, SCT in first remission was recommended for patients with a high risk of relapse (as defined below). Allogeneic SCT was recommended (in the first period mainly for patients younger than 45 years) and autologous SCT was recommended for biologically older patients and for patients lacking a suitable donor. Patients with mature-B-ALL were excluded from this recommendation as the introduction of the 'NHL-BFM 90 protocol' (1994) and SCT were only recommended if remission was not achieved according to standard treatment or after relapse. Conditioning regimen for SCT and GVHD prophylaxis were decided by institutional guidelines at each transplantation centre.
Patients were identified through registers of two previous national studies, each centre's EBMT register and the transplantation records of each centre. In total, 187 patients underwent transplantation during this period. Data confirming and characterising the leukaemia, pretransplant treatment, transplantation, GVHD, complications and outcome were collected from these sources and from the patients' medical charts. The end of follow-up was May 2003.
Of the 187 patients who underwent SCT, 65 patients were treated according to the 1986-1993 protocol; 103 according to the 1994-2000 protocol; and 19 according to other protocols. Clinical characteristics of the patients are presented in Table 2 . Times from diagnosis to SCT were 5.472.5 months (mean7s.d.) for patients in first remission and 22.0717.5 months for patients beyond first remission. At the time of SCT, the majority of patients fulfilled criteria for a high relapse risk or were beyond first remission. However, an additional 22 patients were accepted for transplantation in first remission. The median follow-up time from SCT was: 89 months (17-197 months) for surviving patients; 99 months (57-197 months) for autologous SCT; 92 months months) RD; and 48 months (18-105 months) for URD SCT. All regional ethics committees approved the study. (20) 9 (13) 18 (23) 10 (24) a High-risk leukaemia defined as t (9, 22) , WBC count 430 Â 10 9 /l, CNS leukemia, AUL and/or late remission in addition to mature B-ALL until 1994 and t(4,11) after 1994. b Late remission defined as more than one induction course to achieve remission.
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Definition of high risk of relapse
High risk of relapse was defined as the presence of the Ph chromosome, white blood cell count 430 Â 10 9 /l, CNS leukaemia, AUL and/or late remission. In addition, a mature B immune phenotype was considered as a high-risk criterion in the 1986-1993 protocol and the presence of the t(4,11) karyotype was considered as a high-risk criterion in the 1994-2000 protocol. Ph-positive ALL was diagnosed with conventional cytogenetics t (9, 22) and/or the detection of BCR-ABL with reverse transcriptase-polymerase chain reaction or in situ hybridisation.
Transplantation procedures
Stem cell source, conditioning regimen and GVHD prophylaxis are shown in Table 3 . The majority of both allogeneic and autologous transplant patients (80%) received a conditioning regimen including cyclophosphamide and total body irradiation (TBI). The most common GVHD prophylaxis after allogeneic SCT (82%) was cyclosporine in combination with methotrexate. Seven patients received a T-cell-depleted graft and two patients received reduced intensity conditioning. Three patients underwent a double autologous SCT in first remission. Nine patients underwent a second transplant after relapse. Donor and recipient were considered matched when identical at HLA-A, -B and -DR B1 loci.
Acute and chronic GVHD
Acute and chronic GVHD were graded according to previously published criteria. 12, 13 Chronic GVHD was only assessed in patients who survived at least 100 days after transplantation.
Statistical analysis
Overall survival (OS) was defined as the time from transplantation to death from any cause, and DFS was defined as the time from transplantation to relapse or death. Treatment-related mortality (TRM) was defined as death due to infection, multiple organ failure or GVHD for patients in continuous complete remission. Distribution of patient pre-treatment characteristics between the transplantation types was analysed with the w 2 -test. OS and DFS were estimated by the Kaplan-Meier method and differences between patient subgroups were tested using the log-rank test (Mantel-Cox). Confidence intervals (CI) of 95% were obtained. Prognostic factors for DFS were evaluated with univariate and multiple analyses using Cox's proportional hazard regression. Differences between subgroups were investigated with Fisher's exact test. One patient, who received a syngeneic SCT in first remission, was statistically analysed together with the autologous SCTs.
Results
GVHD
Acute and/or chronic GVHD was present in 83% of the allogeneic transplant patients. Information concerning acute GVHD was collected in 118/120 patients (distribution was none, 26%; grade I-II, 65%; and grade 4II, 9%) and concerning chronic GVHD in 94/99 (distribution was none, 43%; limited, 44%; and extensive, 13%). No association between the frequencies of GVHD and source of stem cells was observed (data not shown).
OS and DFS
The 5-year OS for all patients was 30% (CI 23-36%) and 26% (CI 20-32%) for DFS with no differences between men and women. Two patients received reduced-intensity conditioning; one died after relapsing and the other was alive at first remission after 21 months. Both were excluded from further analysis. DFS was higher 32% (CI 24-40%) for patients transplanted in first remission compared to 14% (CI 5-23%; Po0.0001) in patients transplanted beyond first remission (Figure 1 ). There was no significant difference (P ¼ 0.06) but a trend towards higher DFS for RD vs autologous and URD SCT (Figure 2 ). With the exception that a larger proportion of patients receiving an allogenic graft, as compared to autologous graft, were beyond first remission, (P ¼ 0.04 RD vs autologous, P ¼ 0.006 URD vs autologous w 2 -test), no significant difference was observed in the distribution between transplantation types or prognostic factors.
Prognostic factors were evaluated with univariate analyses and with DFS as an end point (Table 4) . SCT in first remission vs beyond first remission remained an important positive factor both in autologous and allogeneic SCT Table 3 Stem cell source, conditioning and immunosuppression None of the 10 patients with severe acute GVHD (grade III-IV) survived; five died of leukaemia and five of TRM. DFS was significantly better for patients with limited chronic GVHD compared to patients without chronic GVHD, evaluated both by hazard ratio and log-rank test (Figure 3) . Donor type was important in decreased DFS with respect to URD, mismatch and donor/recipient combination male/female and female/male. Further analyses were conducted with multiple Cox's regression analysis as summarised for allogeneic SCT in Table 5 . Transplantation in first remission (P ¼ 0.007) and limited chronic GVHD in contrast to no chronic GVHD (P ¼ 0.007) remained independent factors associated with improved DFS. Transplantation with an URD (P ¼ 0.02), higher age (as a continuous variable: P ¼ 0.03), acute GVHD grade III-IV (P ¼ 0.03) and female donor to male recipient (P ¼ 0.06) appeared to be associated with impaired DFS. However, the P-values should be interpreted 
Transplantation in first remission
For patients transplanted in first remission, no significant difference in the 5-year DFS between patients who underwent autologous (28%, CI 16-40%), RD (40%, CI 26-53%) or URD (27%, CI 9-46%) SCT (P ¼ 0.11) was determined. In addition, there was no difference in 5-year DFS between patients aged 16-39 or 40-66 years with respect to type of transplant ( Figure 4) . The DFS at 5-year for patients with high-risk factors for relapse was 30% (CI 21-40%) compared to 40% (CI 21-59%: NS P ¼ 0.45) for patients without high-risk factors.
Transplantation beyond first remission
The 5-year DFS for all patients transplanted beyond first remission was 14% (5-23%). For patients who suffered an early relapse (with less than 2 years from diagnosis to transplantation), the 5-year DFS was significantly lower at 7% (CI 0-15%) compared to 28% (CI 8-47%, P ¼ 0.04) for patients who underwent SCT more than 2 years from diagnosis. No significant differences (P ¼ 0.59) in 5-year DFS between autologous (6%, CI 0-18%), RD (18%, CI 4-32%) or URD SCT (17%, CI 0-34%) beyond first remission were determined.
Ph-positive patients
Among patients who underwent SCT in first remission, 35/ 124 were Ph-positive and their 5-year DFS was 22% (CI 8-36%), compared to 36% (CI 26-46%) for Phnegative patients (P ¼ 0.12). In first remission, the 5-year DFS was 30% (CI 12-47%) after allogeneic and 0% after autologous transplantation (P ¼ 0.04). For patients transplanted beyond first remission, 7/63 were Ph positive. However, none of these patients survived more than 7 months; one died from TTP-HUS and the other six from leukaemia.
Second transplant after relapse
Of the nine patients who underwent a second transplant after relapse, five had previously received an autologous graft, one a syngeneic, two an RD and one an URD. At second transplant, an autologous transplant was performed in one, RD in two and URD in six patients. Only one patient was alive 46 months after an autologous/URD transplant.
Deaths
Relapse was the dominating cause of death for the autologous, RD and URD SCT patients. However, transplantation mortality was higher and relapse rate lower for RD and URD SCT patients compared with autologuos SCT patients in first remission (P ¼ 0.04) ( Table 6) .
Eight patients (4%) died within the first 30 days after SCT, one after relapse and seven of TRM.
Discussion
Adult ALL patients in Sweden have been treated according to national protocols since 1986. This made it possible to evaluate the outcome for high-risk ALL treated with transplantation as post-remission therapy in a large geographic region. In this study, the most important factor for improved DFS was being in first remission at the time of transplantation. This was despite the fact that the majority of patients transplanted in first remission also had leukaemia with high-risk factors for relapse. Similar results have been reported by some investigators, 14, 15 whereas others 16 have not found any difference between first and beyond first remission. For patients transplanted beyond first remission, a significant difference was found in favour of late relapse vs early relapse (P ¼ 0.04). Transplantation after early relapse resulted in a 5-year DFS of 7%, which cannot be considered a satisfactory outcome of therapy. Reliable prognostic factors may be crucial for identifying patients with a high risk of relapse, thus allowing intensification of treatment in first remission. Quantitative estimation of residual disease may improve prognostic evaluation. [17] [18] [19] [20] Further studies are needed to evaluate the prognostic strength of minimal residual disease and to determine if intensification of treatment will alter the prognosis for this group of patients.
There are conflicting data regarding the benefit of allogeneic SCT in comparison to autologous SCT or chemotherapy for adults with ALL. The prospective LALA-87 trial 21 compares allogeneic SCT to autologous SCT or chemotherapy in first remission and determines a significant difference in favour of allogeneic SCT for highrisk patients but not for standard risk patients. The LALA-94 22 trial confirms the favourable outcome of allogeneic SCT for high-risk patients compared to autologous SCT or chemotherapy. The International Bone Marrow Transplant Registry 23, 24 compares HLA-identical sibling SCT with chemotherapy in first remission and does not find any difference in DFS for patients with or without unfavourable risk factors. Attal et al 25 reported a prospective study from the BGMT group comparing HLA-identical sibling SCT with autologous SCT where higher DFS in the HLAidentical sibling group is found. The ongoing MRC UKALL XII/ECOG E2993 26 study comparing allogeneic SCT with autologous SCT or chemotherapy for Phnegative patients and based on an intent-to-treat analysis report favourable DFS for allogeneic SCT.
Although the study presented did not determine a difference in DFS between allogeneic and autologous SCT, the results indicated that for high-risk leukaemia, DFS may be favourable for RD SCT compared to both URD and autologous SCT. It should be noted that the proportion of patients with adverse prognostic features was higher among allogeneic-transplant patients, and especially among URD patients, than among autotransplant patients, thus obscuring the results of a direct comparison of outcomes. As with other studies, a lower relapse-rate counterbalanced by a higher TRM for allogeneic SCT was found.
The results from the study indicated that, in Sweden, there has been a change in preference from autologous to URD transplantation for patients lacking an acceptable RD: this could be the result of increased access to URDs and increased experience of allogeneic SCT over time. A comparison between autologous SCT and URD SCT revealed no differences in outcome and similar findings have also been described by Wiesdorf et al.
27
No patient with Ph-positive ALL who underwent an autologous transplant in first remission or any SCT beyond first remission survived. DFS for Ph-positive patients who received an allogeneic transplant in first remission was comparable with results for Ph-negative patients. The data suggested that allogeneic transplantation was superior to autologous SCT for Ph-positive patients and this has been confirmed in other studies. [2] [3] [4] Imatinib may be important for the treatment of ALL in the future, 28 possibly in combination with chemotherapy 29 or transplantation, but the effect on long-time survival remains to be examined. In the present situation, an allogeneic transplant in first remission can be recommended for all eligible patients with Ph-positive ALL.
The strength of GVL in ALL has been debated. Several studies support GVHD as an important favourable prognostic factor for survival, 5-7 whereas others do not confirm this association. 14 We report a significant difference in DFS in favour of limited chronic GVHD vs no chronic GVHD, thus supporting previous reports of a clinically important GVL effect in ALL.
Donor/recipient compatibility is known as an important factor for survival and TRM, with inferior outcome for HLA-mismatched donors and recipients. 5, 30 In this study, both mismatched donor/recipients and URDs were significantly associated with inferior DFS on univariate analysis, but only SCT with URDs remained significant in the multiple analyses. From the EBMT registry, Gorin et al 31 reported that the combination of a female donor for a male recipient is one of three adverse prognostic factors found to decrease leukaemia-free survival for RD transplantation in first remission in adult ALL. The current results indicated an impaired DFS for the donor/recipient combination female/male, which was in agreement with previous results.
In conclusion, we report improved DFS in favour of transplantation in first remission vs beyond first remission. Allogeneic transplantation, preferably in first remission, was superior for Ph-positive patients. For all patients, we were not able to confirm a difference between autologous and allogeneic transplantation, even if the results indicate a favourable outcome for RD SCT. The presence of limited chronic GVHD results in higher DFS, indicating a clinically important GVL effect.
